EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CT Mucus Score and 129Xe MRI Ventilation Defects After 2.5 Years’ Anti-IL-5Rα in Eosinophilic Asthma

Marrissa J McIntosh, Harkiran K Kooner, Rachel L Eddy, Angela Wilson, Hana Serajeddini, Anurag Bhalla, Christopher Licskai, Constance A Mackenzie, Cory Yamashita, Grace Parraga

CHEST · 2023-07 · 164 (1) · 27-38

DOI: 10.1016/j.chest.2023.02.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHEST, 2023-07. Verfasst von Marrissa J McIntosh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Robarts Research Institute; Department of Medical Biophysics, Western University, London, ON, Canada. Hauptthemen laut MEDLINE: Asthma, Pulmonary Eosinophilia, Airway Obstruction, Anti-Asthmatic Agents. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Natural Sciences and Engineering Research Council of Canada, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We previously showed in patients with poorly controlled eosinophilic asthma that a single dose of benralizumab resulted in significantly improved Asthma Control Questionnaire (ACQ-6) score and 129Xe MRI ventilation defect percent (VDP) 28 days postinjection, and 129Xe MRI VDP and CT airway mucus occlusions were shown to independently predict this early ACQ-6 response to benralizumab. RESEARCH QUESTION: Do early VDP responses at 28 days persist, and do FEV1, fractional exhaled nitric oxide, and mucus plug score improve during a 2.5 year treatment period? STUDY DESIGN AND METHODS: Participants with poorly controlled eosinophilic asthma completed spirometry, ACQ-6, and MRI, 28 days, 1 year, and 2.5 years after initiation of treatment with benralizumab; chest CT was acquired at enrollment and 2.5 years later. RESULTS: Of 29 participants evaluated at 28 days post-benralizumab, 16 participants returned for follow-up while on therapy at 1 year, and 13 participants were evaluable while on therapy at 2.5 years post-benralizumab initiation. As compared with 28 days post-benralizumab, ACQ-6 score (2.0 ± 1.4) significantly improved after 1 year (0.5 ± 0.6, P = .02; 95% CI, 0.1-1.1) and 2.5 years (0.5 ± 0.5, P = .03; 95% CI, 0.1-1.1). The mean VDP change at 2.5 years (-4% ± 3%) was greater than the minimal clinically important difference, but not significantly different from VDP measured 28 days post-benralizumab. Mucus score (3 ± 4) was significantly improved at 2.5 years (1 ± 1, P = .03; 95% CI, 0.3-5.5). In six of eight participants with previous occlusions, mucus plugs vanished or substantially diminished 2.5 years later. VDP (P < .001) and mucus score (P < .001) measured at baseline, but not fractional exhaled nitric oxide or FEV1, independently predicted ACQ-6 score after 2.5 years. INTERPRETATION: In poorly controlled eosinophilic asthma, early MRI VDP responses at 28 days post-benralizumab persisted 2.5 years later, alongside significantly improved mucus scores and asthma control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaPulmonary EosinophiliaAirway ObstructionAnti-Asthmatic AgentsHumansNitric OxideMucusMagnetic Resonance ImagingTomography, X-Ray Computed

Stichwörter der Autor:innen

(129)Xe MRIairway occlusionsbenralizumabeosinophilic asthmamucus score

Substanzen

Nitric OxideAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Robarts Research Institute; Department of Medical Biophysics, Western University, London, ON, Canada.
  • University of British Columbia Centre for Heart Lung Innovation, St. Paul's Hospital Vancouver, Vancouver, BC, Canada.
  • Robarts Research Institute.
  • Robarts Research Institute; Division of Respirology.
  • Division of Respirology.
  • Division of Respirology; Division of Clinical Pharmacology and Toxicology, Department of Medicine, Western University, London, ON, Canada.

Förderung

  • CIHR
  • Natural Sciences and Engineering Research Council of Canada
  • AstraZeneca
  • Michael Smith Health Research BC
  • Canadian Allergy, Asthma and Immunology Foundation
  • Reseau canadien de recherche respiratoire
  • AstraZeneca Canada Inc
  • Canadian Institutes of Health Research

Zitieren

APA

McIntosh, M. J., Kooner, H. K., Eddy, R. L., Wilson, A., Serajeddini, H., Bhalla, A., Licskai, C., Mackenzie, C. A., Yamashita, C., & Parraga, G. (2023). CT Mucus Score and 129Xe MRI Ventilation Defects After 2.5 Years’ Anti-IL-5Rα in Eosinophilic Asthma. CHEST, 164(1), 27-38. https://doi.org/10.1016/j.chest.2023.02.009

Vancouver

McIntosh MJ, Kooner HK, Eddy RL, Wilson A, Serajeddini H, Bhalla A, et al. CT Mucus Score and 129Xe MRI Ventilation Defects After 2.5 Years’ Anti-IL-5Rα in Eosinophilic Asthma. CHEST. 2023;164(1):27-38. doi:10.1016/j.chest.2023.02.009

BibTeX
@article{McIntosh2023,
  author = {McIntosh, Marrissa J and Kooner, Harkiran K and Eddy, Rachel L and Wilson, Angela and Serajeddini, Hana and Bhalla, Anurag and Licskai, Christopher and Mackenzie, Constance A and Yamashita, Cory and Parraga, Grace},
  title = {CT Mucus Score and 129Xe MRI Ventilation Defects After 2.5 Years’ Anti-IL-5Rα in Eosinophilic Asthma},
  journal = {CHEST},
  year = {2023},
  volume = {164},
  number = {1},
  pages = {27--38},
  doi = {10.1016/j.chest.2023.02.009}
}
Kostenlos starten →